A Phase II Trial of Atezolizumab plus Chemotherapy after Progression on Single Agent PD-1 or PD-L1 Inhibitor in Cisplatin-ineligible Patients with Advanced Urothelial Carcinoma

Learn more:

• clinicaltrials.gov: #NCT03737123
• News release

Abstracts/Posters/Presentations:

• Nabil Adra, Ralph J. Hauke, Hristos Z. Kaimakliotis, Shuchi Gulati, Neda Hashemi, Roberto Pili. Phase II trial of atezolizumab plus chemotherapy after progression on single-agent PD-1 or PD-L1 inhibitor in cisplatin ineligible patients with advanced urothelial carcinoma HCRN GU17-295. Presented as Trials In Progress Poster at the 2020 Genitourinary Cancers Symposium, February 14, 2020. J Clin Oncol 38, 2020 (suppl 6; abstr TPS587). See abstract.